DLin-KC2-DMA is a key ionizable lipid widely used in the development of lipid nanoparticles (LNPs) for nucleic acid delivery, encompassing both mRNA therapeutics and siRNA-based treatments. Its primary role is as a component of the lipid formulation in LNPs, where it facilitates the encapsulation, protection, and efficient intracellular delivery of genetic material such as mRNA or siRNA. This chemical has been instrumental in approved therapies like Onpattro (patisiran), an siRNA drug for hereditary transthyretin-mediated amyloidosis, by enhancing stability and endosomal escape. It is also critical in mRNA vaccines, such as those for COVID-19, improving cellular uptake and immunogenicity. Furthermore, DLin-KC2-DMA is explored in gene therapy and treatments for various genetic disorders, enabling targeted delivery to specific tissues and organs, thereby advancing the efficacy and safety of nucleic acid-based medicines in biotechnology and medicine.